GLP-1 Maintenance Dosing: Clinical Evidence for Sustained Weight Management
Obesity treatment utilising GLP-1 receptor agonists yields substantial weight loss outcomes. However, discontinuing these pharmacological agents often leads to…
-
-
GLP-1 Growth Drives Concentration Risk in Pharmaceutical Research
The pharmaceutical research returns have reached a multi-year high due to the surging demand for glucagon-like peptide-1 receptor agonists….
-
Eli Lilly Reports Robust First Quarter Financial Results
Eli Lilly reported first-quarter results that surpassed market expectations. Management subsequently raised full-year revenue and earnings guidance. This revision…
-
US Prescription Drug Spending Approaches $1 Trillion, Fueled by GLP-1 Market Surge
Spending on prescription drugs just hit $915 billion. Compared to the previous year, this number shows a rise of…
-
Eli Lilly Raises 2026 Forecasts as GLP-1 Drug Demand Surges Globally
Recently, Eli Lilly revised its profit and revenue projections for the full year upward. This adjustment comes in response…
-
Endoscopic Procedure May Mitigate Weight Regain After Medication Discontinuation
Interim results from the REMAIN-1 clinical trial indicate a promising outpatient procedure. Duodenal mucosal resurfacing appears to reduce weight…
-
Menopausal Hormone Therapy Combined With Tirzepatide Linked to Greater Weight Loss in Postmenopausal Women
A new study suggests that combining hormone therapy with tirzepatide helps postmenopausal women lose more weight. Researchers found that…
-
Evaluating the Clinical Efficacy of Tirzepatide for Weight Management
Tirzepatide represents a distinct pharmacological advance in modern obesity treatment. The manufacturer markets this medication as Mounjaro for diabetes…
-
CagriSema Falls Short of Tirzepatide in Pivotal Obesity Trial Showdown, affecting Novo Stocks
Shares of Novo Nordisk fell sharply after the company reported disappointing results from a closely watched obesity drug trial….
